Postpartum uterine diseases, such as puerperal metrity and clinical endometritis can affect more than 40% of cows in dairy farms. Whatever their severity, these diseases are one of the main reasons for fertility loyalty, causing declines in the productivity of dairy cows and therefore leading to economic losses. Although uterine diseases have been the subject of scientific discussion for many years, but it was not possible to agree on uniform definitions for different types of events. Including technical innovations and testing procedures, enormous scientific progress and more in-depth knowledge of physiology as well as pathological mechanisms have been achieved. Bovine metris and endometritis can be considered multifactorial diseases caused by a combination of microbial infection, immune system dysregulation and additional risk factors.
These interactions were analyzed on microbial and molecular biological levels as well as the use of bioinformatics and molecular genetics. As a result, new species of bacteria and inflammatory mediators possibly contribute to the development of uterine diseases have recently been described. In addition, metabolic and genetic risk factors and roles due to fertility deficiency have been evaluated. In conclusion, it was possible to identify new approaches for possible therapeutic and preventive methods, of which a subset can already be implemented in a daily practical routine. This article provides an overview of recent scientific results for bovine metritis and endometritis with a focus on microbial, microbiological and immunological studies.
Comparison of student performances by evaluation through a structured practical examination objective with respect to the conventional method of the second year of MBB students in microbiology
Introduction: The structured practical examination (OSPE) is a complete evaluation tool. We wanted to improve our evaluation methods and make it a more skill-based assessment. Thus, this study was designed to compare the effectiveness of the practical review of the structured objectives with that of the conventional practical examination.
Methods: This interventional study was conducted in the Atciimsh Microbiology Department, Lucknow over six months from October 2019 to March 20, 2019. A hundred MBB students of the year were registered. Students were divided into two offulty groups for the conventional review group (controls) and the OSPE group. The first day, the cases appeared for the OSPE while the conventional examination checks. On the second day, the groups were crossed. Students appearing for the Ospewere evaluated by their scores in different stations. The feedback forms with a pre-tutored questionnaire were given to students and examiners after OSPE two days to record their perceptions. Finally, students’ scores have been tabulated and compared. Microsoft Excel and SPSS were used for data analysis. The data were presented in percentages, average and standard deviation. The T test student was used and the meaning has been verified using the value p <0.05.
Results: Overall, in the OSPE, students marked higher and the result was statistically significant. The proportion of students in the upper brand range was more for OSPE Typethat for the conventional method. The difference was statistically significant (p <0.001) .Feedback taken from examiners as well as students in the form of remote-controlled questionnaire to analyze their perceptions was very encouraging.
Conclusions: OSPE is a complete evaluation modality for the practical assessment of MBBS students. OSPE has been an effective tool that improved the forms of microbiology students.
[Bovine uterine diseases: Aspects of microbiology, molecular biology, and immunology]
Anatomical graduate in the microbiology of the merger of the spine infection and resistance to surgical antimicrobial prophylaxis
Study design: Hospital retrospective study-register.
Objective: To characterize the microbial epidemiology of surgical site infection (SSI) in the surgery of the vertebral column melting ad the charge of the standard surgical antibiotic prophylaxis resistance.
Summary of basic data: SSI persists as a state-of-the-art complication of spine melting surgery despite the growth of improved recovery programs and improvements in other surgical measurements. Improved understanding of SSI microbiology and common mechanisms for current prevention strategies are required to inform the development of new prevention approaches relevant to modern surgical practice. Methods: The melting cases of the spine carried out at a single reference center between January 2011 and June 2019 were reviewed and the SSI cases meeting the national health care system criteria were identified. Using microbiological and procedural data for each case, we analyzed the anatomical distribution of pathogens, their differential time on presentation and correlation with staphylococcus filtering results resistant to methicillin. The susceptibility of isolates grown from each infection has been compared to the spectrum of the surgical antibiotic prophylaxis administered during the index procedure on a case-by-case basis. The susceptibility to alternate prophylactic agents has also been modeled.
Results: Of 6727 cases, 351 infections took place within 90 days. An anatomical gradient of the microbiology of SSI has been observed on the length of the back, passing from the cutaneous flora (gram-positive) in the cervical column with the enteric flora (gram-negative / anaerobic) in the Lumbosacrale region (coefficient of Correlation 0.94, p <0.001). The majority (57.5%) of infections were resistant to prophylaxis administered during the proceedings. Cephalosporin-resistant gram-negative infection was common at the LUMBOSACRAL levels and unsecured methicillin resistance was common at the cervical levels.
Description: A polyclonal antibody for CD9 from Human | Mouse | Rat. The antibody is produced in rabbit after immunization with A synthesized peptide. The Antibody is tested and validated for WB, IHC, ICC/IF assays with the following recommended dilutions: WB (1:1000), IHC (1:200), ICC/IF (1:200). This CD9 antibody is unconjugated.
Description: A polyclonal antibody for CD9 from Human | Mouse | Rat. The antibody is produced in rabbit after immunization with A synthesized peptide. The Antibody is tested and validated for WB, IHC, ICC/IF assays with the following recommended dilutions: WB (1:1000), IHC (1:200), ICC/IF (1:200). This CD9 antibody is conjugated to ATTO 390.
Description: A polyclonal antibody for CD9 from Human | Mouse | Rat. The antibody is produced in rabbit after immunization with A synthesized peptide. The Antibody is tested and validated for WB, IHC, ICC/IF assays with the following recommended dilutions: WB (1:1000), IHC (1:200), ICC/IF (1:200). This CD9 antibody is conjugated to ATTO 488.
Description: A polyclonal antibody for CD9 from Human | Mouse | Rat. The antibody is produced in rabbit after immunization with A synthesized peptide. The Antibody is tested and validated for WB, IHC, ICC/IF assays with the following recommended dilutions: WB (1:1000), IHC (1:200), ICC/IF (1:200). This CD9 antibody is conjugated to ATTO 565.
Description: A polyclonal antibody for CD9 from Human | Mouse | Rat. The antibody is produced in rabbit after immunization with A synthesized peptide. The Antibody is tested and validated for WB, IHC, ICC/IF assays with the following recommended dilutions: WB (1:1000), IHC (1:200), ICC/IF (1:200). This CD9 antibody is conjugated to ATTO 594.
Description: A polyclonal antibody for CD9 from Human | Mouse | Rat. The antibody is produced in rabbit after immunization with A synthesized peptide. The Antibody is tested and validated for WB, IHC, ICC/IF assays with the following recommended dilutions: WB (1:1000), IHC (1:200), ICC/IF (1:200). This CD9 antibody is conjugated to ATTO 633.
Description: A polyclonal antibody for CD9 from Human | Mouse | Rat. The antibody is produced in rabbit after immunization with A synthesized peptide. The Antibody is tested and validated for WB, IHC, ICC/IF assays with the following recommended dilutions: WB (1:1000), IHC (1:200), ICC/IF (1:200). This CD9 antibody is conjugated to ATTO 655.
Description: A polyclonal antibody for CD9 from Human | Mouse | Rat. The antibody is produced in rabbit after immunization with A synthesized peptide. The Antibody is tested and validated for WB, IHC, ICC/IF assays with the following recommended dilutions: WB (1:1000), IHC (1:200), ICC/IF (1:200). This CD9 antibody is conjugated to ATTO 680.
Description: A polyclonal antibody for CD9 from Human | Mouse | Rat. The antibody is produced in rabbit after immunization with A synthesized peptide. The Antibody is tested and validated for WB, IHC, ICC/IF assays with the following recommended dilutions: WB (1:1000), IHC (1:200), ICC/IF (1:200). This CD9 antibody is conjugated to ATTO 700.
Description: A polyclonal antibody for CD9 from Human | Mouse | Rat. The antibody is produced in rabbit after immunization with A synthesized peptide. The Antibody is tested and validated for WB, IHC, ICC/IF assays with the following recommended dilutions: WB (1:1000), IHC (1:200), ICC/IF (1:200). This CD9 antibody is conjugated to Alkaline Phosphatase.
Description: A polyclonal antibody for CD9 from Human | Mouse | Rat. The antibody is produced in rabbit after immunization with A synthesized peptide. The Antibody is tested and validated for WB, IHC, ICC/IF assays with the following recommended dilutions: WB (1:1000), IHC (1:200), ICC/IF (1:200). This CD9 antibody is conjugated to APC .
Description: A polyclonal antibody for CD9 from Human | Mouse | Rat. The antibody is produced in rabbit after immunization with A synthesized peptide. The Antibody is tested and validated for WB, IHC, ICC/IF assays with the following recommended dilutions: WB (1:1000), IHC (1:200), ICC/IF (1:200). This CD9 antibody is conjugated to APC/Cy7.
Description: A polyclonal antibody for CD9 from Human | Mouse | Rat. The antibody is produced in rabbit after immunization with A synthesized peptide. The Antibody is tested and validated for WB, IHC, ICC/IF assays with the following recommended dilutions: WB (1:1000), IHC (1:200), ICC/IF (1:200). This CD9 antibody is conjugated to Biotin.
Description: A polyclonal antibody for CD9 from Human | Mouse | Rat. The antibody is produced in rabbit after immunization with A synthesized peptide. The Antibody is tested and validated for WB, IHC, ICC/IF assays with the following recommended dilutions: WB (1:1000), IHC (1:200), ICC/IF (1:200). This CD9 antibody is conjugated to Dylight 350.
Description: A polyclonal antibody for CD9 from Human | Mouse | Rat. The antibody is produced in rabbit after immunization with A synthesized peptide. The Antibody is tested and validated for WB, IHC, ICC/IF assays with the following recommended dilutions: WB (1:1000), IHC (1:200), ICC/IF (1:200). This CD9 antibody is conjugated to Dylight 405.
Description: A polyclonal antibody for CD9 from Human | Mouse | Rat. The antibody is produced in rabbit after immunization with A synthesized peptide. The Antibody is tested and validated for WB, IHC, ICC/IF assays with the following recommended dilutions: WB (1:1000), IHC (1:200), ICC/IF (1:200). This CD9 antibody is conjugated to Dylight 488.
Description: A polyclonal antibody for CD9 from Human | Mouse | Rat. The antibody is produced in rabbit after immunization with A synthesized peptide. The Antibody is tested and validated for WB, IHC, ICC/IF assays with the following recommended dilutions: WB (1:1000), IHC (1:200), ICC/IF (1:200). This CD9 antibody is conjugated to Dylight 594.
Description: A polyclonal antibody for CD9 from Human | Mouse | Rat. The antibody is produced in rabbit after immunization with A synthesized peptide. The Antibody is tested and validated for WB, IHC, ICC/IF assays with the following recommended dilutions: WB (1:1000), IHC (1:200), ICC/IF (1:200). This CD9 antibody is conjugated to Dylight 633.
Description: A polyclonal antibody for CD9 from Human | Mouse | Rat. The antibody is produced in rabbit after immunization with A synthesized peptide. The Antibody is tested and validated for WB, IHC, ICC/IF assays with the following recommended dilutions: WB (1:1000), IHC (1:200), ICC/IF (1:200). This CD9 antibody is conjugated to FITC.
Description: A polyclonal antibody for CD9 from Human | Mouse | Rat. The antibody is produced in rabbit after immunization with A synthesized peptide. The Antibody is tested and validated for WB, IHC, ICC/IF assays with the following recommended dilutions: WB (1:1000), IHC (1:200), ICC/IF (1:200). This CD9 antibody is conjugated to HRP.
Description: A polyclonal antibody for CD9 from Human | Mouse | Rat. The antibody is produced in rabbit after immunization with A synthesized peptide. The Antibody is tested and validated for WB, IHC, ICC/IF assays with the following recommended dilutions: WB (1:1000), IHC (1:200), ICC/IF (1:200). This CD9 antibody is conjugated to PE/ATTO 594.
Description: A polyclonal antibody for CD9 from Human | Mouse | Rat. The antibody is produced in rabbit after immunization with A synthesized peptide. The Antibody is tested and validated for WB, IHC, ICC/IF assays with the following recommended dilutions: WB (1:1000), IHC (1:200), ICC/IF (1:200). This CD9 antibody is conjugated to PerCP.
Description: A polyclonal antibody for CD9 from Human | Mouse | Rat. The antibody is produced in rabbit after immunization with A synthesized peptide. The Antibody is tested and validated for WB, IHC, ICC/IF assays with the following recommended dilutions: WB (1:1000), IHC (1:200), ICC/IF (1:200). This CD9 antibody is conjugated to RPE .
Description: A polyclonal antibody for CD9 from Human | Mouse | Rat. The antibody is produced in rabbit after immunization with A synthesized peptide. The Antibody is tested and validated for WB, IHC, ICC/IF assays with the following recommended dilutions: WB (1:1000), IHC (1:200), ICC/IF (1:200). This CD9 antibody is conjugated to Streptavidin.
Description: A polyclonal antibody for KDEL from Human | Mouse | Rat. The antibody is produced in rabbit after immunization with KDEL containing peptide immunogen. The Antibody is tested and validated for WB, ICC/IF, IHC assays with the following recommended dilutions: WB (1:1000), ICC/IF (1:100). This KDEL antibody is unconjugated.
Description: A polyclonal antibody for KDEL from Human | Mouse | Rat. The antibody is produced in rabbit after immunization with KDEL containing peptide immunogen. The Antibody is tested and validated for WB, ICC/IF, IHC assays with the following recommended dilutions: WB (1:1000), ICC/IF (1:100). This KDEL antibody is unconjugated.
Description: A polyclonal antibody for KDEL from Human | Mouse | Rat. The antibody is produced in rabbit after immunization with KDEL containing peptide immunogen. The Antibody is tested and validated for WB, ICC/IF, IHC assays with the following recommended dilutions: WB (1:1000), ICC/IF (1:100). This KDEL antibody is conjugated to ATTO 390.
Description: A polyclonal antibody for KDEL from Human | Mouse | Rat. The antibody is produced in rabbit after immunization with KDEL containing peptide immunogen. The Antibody is tested and validated for WB, ICC/IF, IHC assays with the following recommended dilutions: WB (1:1000), ICC/IF (1:100). This KDEL antibody is conjugated to ATTO 488.
Description: A polyclonal antibody for KDEL from Human | Mouse | Rat. The antibody is produced in rabbit after immunization with KDEL containing peptide immunogen. The Antibody is tested and validated for WB, ICC/IF, IHC assays with the following recommended dilutions: WB (1:1000), ICC/IF (1:100). This KDEL antibody is conjugated to ATTO 565.
Description: A polyclonal antibody for KDEL from Human | Mouse | Rat. The antibody is produced in rabbit after immunization with KDEL containing peptide immunogen. The Antibody is tested and validated for WB, ICC/IF, IHC assays with the following recommended dilutions: WB (1:1000), ICC/IF (1:100). This KDEL antibody is conjugated to ATTO 594.
Description: A polyclonal antibody for KDEL from Human | Mouse | Rat. The antibody is produced in rabbit after immunization with KDEL containing peptide immunogen. The Antibody is tested and validated for WB, ICC/IF, IHC assays with the following recommended dilutions: WB (1:1000), ICC/IF (1:100). This KDEL antibody is conjugated to ATTO 633.
Description: A polyclonal antibody for KDEL from Human | Mouse | Rat. The antibody is produced in rabbit after immunization with KDEL containing peptide immunogen. The Antibody is tested and validated for WB, ICC/IF, IHC assays with the following recommended dilutions: WB (1:1000), ICC/IF (1:100). This KDEL antibody is conjugated to ATTO 655.
Description: A polyclonal antibody for KDEL from Human | Mouse | Rat. The antibody is produced in rabbit after immunization with KDEL containing peptide immunogen. The Antibody is tested and validated for WB, ICC/IF, IHC assays with the following recommended dilutions: WB (1:1000), ICC/IF (1:100). This KDEL antibody is conjugated to ATTO 680.
Description: A polyclonal antibody for KDEL from Human | Mouse | Rat. The antibody is produced in rabbit after immunization with KDEL containing peptide immunogen. The Antibody is tested and validated for WB, ICC/IF, IHC assays with the following recommended dilutions: WB (1:1000), ICC/IF (1:100). This KDEL antibody is conjugated to ATTO 700.
Description: A polyclonal antibody for KDEL from Human | Mouse | Rat. The antibody is produced in rabbit after immunization with KDEL containing peptide immunogen. The Antibody is tested and validated for WB, ICC/IF, IHC assays with the following recommended dilutions: WB (1:1000), ICC/IF (1:100). This KDEL antibody is conjugated to Alkaline Phosphatase.
Description: A polyclonal antibody for KDEL from Human | Mouse | Rat. The antibody is produced in rabbit after immunization with KDEL containing peptide immunogen. The Antibody is tested and validated for WB, ICC/IF, IHC assays with the following recommended dilutions: WB (1:1000), ICC/IF (1:100). This KDEL antibody is conjugated to APC .
Description: A polyclonal antibody for KDEL from Human | Mouse | Rat. The antibody is produced in rabbit after immunization with KDEL containing peptide immunogen. The Antibody is tested and validated for WB, ICC/IF, IHC assays with the following recommended dilutions: WB (1:1000), ICC/IF (1:100). This KDEL antibody is conjugated to APC/Cy7.
Description: A polyclonal antibody for KDEL from Human | Mouse | Rat. The antibody is produced in rabbit after immunization with KDEL containing peptide immunogen. The Antibody is tested and validated for WB, ICC/IF, IHC assays with the following recommended dilutions: WB (1:1000), ICC/IF (1:100). This KDEL antibody is conjugated to Biotin.
Description: A polyclonal antibody for KDEL from Human | Mouse | Rat. The antibody is produced in rabbit after immunization with KDEL containing peptide immunogen. The Antibody is tested and validated for WB, ICC/IF, IHC assays with the following recommended dilutions: WB (1:1000), ICC/IF (1:100). This KDEL antibody is conjugated to Dylight 350.
Description: A polyclonal antibody for KDEL from Human | Mouse | Rat. The antibody is produced in rabbit after immunization with KDEL containing peptide immunogen. The Antibody is tested and validated for WB, ICC/IF, IHC assays with the following recommended dilutions: WB (1:1000), ICC/IF (1:100). This KDEL antibody is conjugated to Dylight 405.
Description: A polyclonal antibody for KDEL from Human | Mouse | Rat. The antibody is produced in rabbit after immunization with KDEL containing peptide immunogen. The Antibody is tested and validated for WB, ICC/IF, IHC assays with the following recommended dilutions: WB (1:1000), ICC/IF (1:100). This KDEL antibody is conjugated to Dylight 488.
Description: A polyclonal antibody for KDEL from Human | Mouse | Rat. The antibody is produced in rabbit after immunization with KDEL containing peptide immunogen. The Antibody is tested and validated for WB, ICC/IF, IHC assays with the following recommended dilutions: WB (1:1000), ICC/IF (1:100). This KDEL antibody is conjugated to Dylight 594.
Description: A polyclonal antibody for KDEL from Human | Mouse | Rat. The antibody is produced in rabbit after immunization with KDEL containing peptide immunogen. The Antibody is tested and validated for WB, ICC/IF, IHC assays with the following recommended dilutions: WB (1:1000), ICC/IF (1:100). This KDEL antibody is conjugated to Dylight 633.
Description: A polyclonal antibody for KDEL from Human | Mouse | Rat. The antibody is produced in rabbit after immunization with KDEL containing peptide immunogen. The Antibody is tested and validated for WB, ICC/IF, IHC assays with the following recommended dilutions: WB (1:1000), ICC/IF (1:100). This KDEL antibody is conjugated to FITC.
Description: A polyclonal antibody for KDEL from Human | Mouse | Rat. The antibody is produced in rabbit after immunization with KDEL containing peptide immunogen. The Antibody is tested and validated for WB, ICC/IF, IHC assays with the following recommended dilutions: WB (1:1000), ICC/IF (1:100). This KDEL antibody is conjugated to HRP.
Description: A polyclonal antibody for KDEL from Human | Mouse | Rat. The antibody is produced in rabbit after immunization with KDEL containing peptide immunogen. The Antibody is tested and validated for WB, ICC/IF, IHC assays with the following recommended dilutions: WB (1:1000), ICC/IF (1:100). This KDEL antibody is conjugated to PE/ATTO 594.
Description: A polyclonal antibody for KDEL from Human | Mouse | Rat. The antibody is produced in rabbit after immunization with KDEL containing peptide immunogen. The Antibody is tested and validated for WB, ICC/IF, IHC assays with the following recommended dilutions: WB (1:1000), ICC/IF (1:100). This KDEL antibody is conjugated to PerCP.
Description: A polyclonal antibody for KDEL from Human | Mouse | Rat. The antibody is produced in rabbit after immunization with KDEL containing peptide immunogen. The Antibody is tested and validated for WB, ICC/IF, IHC assays with the following recommended dilutions: WB (1:1000), ICC/IF (1:100). This KDEL antibody is conjugated to RPE .
Description: A polyclonal antibody for KDEL from Human | Mouse | Rat. The antibody is produced in rabbit after immunization with KDEL containing peptide immunogen. The Antibody is tested and validated for WB, ICC/IF, IHC assays with the following recommended dilutions: WB (1:1000), ICC/IF (1:100). This KDEL antibody is conjugated to Streptavidin.
Description: A polyclonal antibody for KDEL from Human | Mouse | Rat. The antibody is produced in rabbit after immunization with KDEL containing peptide immunogen. The Antibody is tested and validated for WB, ICC/IF, IHC assays with the following recommended dilutions: WB (1:1000), ICC/IF (1:100). This KDEL antibody is unconjugated.
Description: A polyclonal antibody for Phosphoserine from Species Independent. The antibody is produced in rabbit after immunization with Phosphoserine conjugated to KLH, and phosvitin mixture. The Antibody is tested and validated for WB, IHC, ICC/IF, IP, ELISA assays with the following recommended dilutions: WB (1:500), ICC/IF (1:50), ELISA (1:250), IP (1:100). This Phosphoserine antibody is unconjugated.
Description: A polyclonal antibody for Phosphoserine from Species Independent. The antibody is produced in rabbit after immunization with Phosphoserine conjugated to KLH, and phosvitin mixture. The Antibody is tested and validated for WB, IHC, ICC/IF, IP, ELISA assays with the following recommended dilutions: WB (1:500), ICC/IF (1:50), ELISA (1:250), IP (1:100). This Phosphoserine antibody is conjugated to ATTO 390.
Description: A polyclonal antibody for Phosphoserine from Species Independent. The antibody is produced in rabbit after immunization with Phosphoserine conjugated to KLH, and phosvitin mixture. The Antibody is tested and validated for WB, IHC, ICC/IF, IP, ELISA assays with the following recommended dilutions: WB (1:500), ICC/IF (1:50), ELISA (1:250), IP (1:100). This Phosphoserine antibody is conjugated to ATTO 488.
Description: A polyclonal antibody for Phosphoserine from Species Independent. The antibody is produced in rabbit after immunization with Phosphoserine conjugated to KLH, and phosvitin mixture. The Antibody is tested and validated for WB, IHC, ICC/IF, IP, ELISA assays with the following recommended dilutions: WB (1:500), ICC/IF (1:50), ELISA (1:250), IP (1:100). This Phosphoserine antibody is conjugated to ATTO 565.
Description: A polyclonal antibody for Phosphoserine from Species Independent. The antibody is produced in rabbit after immunization with Phosphoserine conjugated to KLH, and phosvitin mixture. The Antibody is tested and validated for WB, IHC, ICC/IF, IP, ELISA assays with the following recommended dilutions: WB (1:500), ICC/IF (1:50), ELISA (1:250), IP (1:100). This Phosphoserine antibody is conjugated to ATTO 594.
Description: A polyclonal antibody for Phosphoserine from Species Independent. The antibody is produced in rabbit after immunization with Phosphoserine conjugated to KLH, and phosvitin mixture. The Antibody is tested and validated for WB, IHC, ICC/IF, IP, ELISA assays with the following recommended dilutions: WB (1:500), ICC/IF (1:50), ELISA (1:250), IP (1:100). This Phosphoserine antibody is conjugated to ATTO 633.
Description: A polyclonal antibody for Phosphoserine from Species Independent. The antibody is produced in rabbit after immunization with Phosphoserine conjugated to KLH, and phosvitin mixture. The Antibody is tested and validated for WB, IHC, ICC/IF, IP, ELISA assays with the following recommended dilutions: WB (1:500), ICC/IF (1:50), ELISA (1:250), IP (1:100). This Phosphoserine antibody is conjugated to ATTO 655.
Description: A polyclonal antibody for Phosphoserine from Species Independent. The antibody is produced in rabbit after immunization with Phosphoserine conjugated to KLH, and phosvitin mixture. The Antibody is tested and validated for WB, IHC, ICC/IF, IP, ELISA assays with the following recommended dilutions: WB (1:500), ICC/IF (1:50), ELISA (1:250), IP (1:100). This Phosphoserine antibody is conjugated to ATTO 680.
Description: A polyclonal antibody for Phosphoserine from Species Independent. The antibody is produced in rabbit after immunization with Phosphoserine conjugated to KLH, and phosvitin mixture. The Antibody is tested and validated for WB, IHC, ICC/IF, IP, ELISA assays with the following recommended dilutions: WB (1:500), ICC/IF (1:50), ELISA (1:250), IP (1:100). This Phosphoserine antibody is conjugated to ATTO 700.
Description: A polyclonal antibody for Phosphoserine from Species Independent. The antibody is produced in rabbit after immunization with Phosphoserine conjugated to KLH, and phosvitin mixture. The Antibody is tested and validated for WB, IHC, ICC/IF, IP, ELISA assays with the following recommended dilutions: WB (1:500), ICC/IF (1:50), ELISA (1:250), IP (1:100). This Phosphoserine antibody is conjugated to Alkaline Phosphatase.
Description: A polyclonal antibody for Phosphoserine from Species Independent. The antibody is produced in rabbit after immunization with Phosphoserine conjugated to KLH, and phosvitin mixture. The Antibody is tested and validated for WB, IHC, ICC/IF, IP, ELISA assays with the following recommended dilutions: WB (1:500), ICC/IF (1:50), ELISA (1:250), IP (1:100). This Phosphoserine antibody is conjugated to APC .
Description: A polyclonal antibody for Phosphoserine from Species Independent. The antibody is produced in rabbit after immunization with Phosphoserine conjugated to KLH, and phosvitin mixture. The Antibody is tested and validated for WB, IHC, ICC/IF, IP, ELISA assays with the following recommended dilutions: WB (1:500), ICC/IF (1:50), ELISA (1:250), IP (1:100). This Phosphoserine antibody is conjugated to APC/Cy7.
Description: A polyclonal antibody for Phosphoserine from Species Independent. The antibody is produced in rabbit after immunization with Phosphoserine conjugated to KLH, and phosvitin mixture. The Antibody is tested and validated for WB, IHC, ICC/IF, IP, ELISA assays with the following recommended dilutions: WB (1:500), ICC/IF (1:50), ELISA (1:250), IP (1:100). This Phosphoserine antibody is conjugated to Biotin.
Description: A polyclonal antibody for Phosphoserine from Species Independent. The antibody is produced in rabbit after immunization with Phosphoserine conjugated to KLH, and phosvitin mixture. The Antibody is tested and validated for WB, IHC, ICC/IF, IP, ELISA assays with the following recommended dilutions: WB (1:500), ICC/IF (1:50), ELISA (1:250), IP (1:100). This Phosphoserine antibody is conjugated to Dylight 350.
Description: A polyclonal antibody for Phosphoserine from Species Independent. The antibody is produced in rabbit after immunization with Phosphoserine conjugated to KLH, and phosvitin mixture. The Antibody is tested and validated for WB, IHC, ICC/IF, IP, ELISA assays with the following recommended dilutions: WB (1:500), ICC/IF (1:50), ELISA (1:250), IP (1:100). This Phosphoserine antibody is conjugated to Dylight 405.
Description: A polyclonal antibody for Phosphoserine from Species Independent. The antibody is produced in rabbit after immunization with Phosphoserine conjugated to KLH, and phosvitin mixture. The Antibody is tested and validated for WB, IHC, ICC/IF, IP, ELISA assays with the following recommended dilutions: WB (1:500), ICC/IF (1:50), ELISA (1:250), IP (1:100). This Phosphoserine antibody is conjugated to Dylight 488.
Description: A polyclonal antibody for Phosphoserine from Species Independent. The antibody is produced in rabbit after immunization with Phosphoserine conjugated to KLH, and phosvitin mixture. The Antibody is tested and validated for WB, IHC, ICC/IF, IP, ELISA assays with the following recommended dilutions: WB (1:500), ICC/IF (1:50), ELISA (1:250), IP (1:100). This Phosphoserine antibody is conjugated to Dylight 594.
Description: A polyclonal antibody for Phosphoserine from Species Independent. The antibody is produced in rabbit after immunization with Phosphoserine conjugated to KLH, and phosvitin mixture. The Antibody is tested and validated for WB, IHC, ICC/IF, IP, ELISA assays with the following recommended dilutions: WB (1:500), ICC/IF (1:50), ELISA (1:250), IP (1:100). This Phosphoserine antibody is conjugated to Dylight 633.
Description: A polyclonal antibody for Phosphoserine from Species Independent. The antibody is produced in rabbit after immunization with Phosphoserine conjugated to KLH, and phosvitin mixture. The Antibody is tested and validated for WB, IHC, ICC/IF, IP, ELISA assays with the following recommended dilutions: WB (1:500), ICC/IF (1:50), ELISA (1:250), IP (1:100). This Phosphoserine antibody is conjugated to FITC.
Description: A polyclonal antibody for Phosphoserine from Species Independent. The antibody is produced in rabbit after immunization with Phosphoserine conjugated to KLH, and phosvitin mixture. The Antibody is tested and validated for WB, IHC, ICC/IF, IP, ELISA assays with the following recommended dilutions: WB (1:500), ICC/IF (1:50), ELISA (1:250), IP (1:100). This Phosphoserine antibody is conjugated to PE/ATTO 594.
Description: A polyclonal antibody for Phosphoserine from Species Independent. The antibody is produced in rabbit after immunization with Phosphoserine conjugated to KLH, and phosvitin mixture. The Antibody is tested and validated for WB, IHC, ICC/IF, IP, ELISA assays with the following recommended dilutions: WB (1:500), ICC/IF (1:50), ELISA (1:250), IP (1:100). This Phosphoserine antibody is conjugated to PerCP.
×
Conclusions: Strategies for the prevention of individualized infections adapted to the operative level are necessary in the surgery of the spine. Endogenous contamination of the wound with an enteric flora can be a common mechanism of infection in the bulging melting. New approaches to prophylaxis and prevention should be priorities in this population.
Gina![[Bovine uterine diseases: Aspects of microbiology, molecular biology, and immunology]](https://stainingkit.com/wp-content/uploads/2020/12/IMG-20201217-WA0101.jpg)
![[Bovine uterine diseases: Aspects of microbiology, molecular biology, and immunology]](https://stainingkit.com/wp-content/uploads/2020/12/IMG-20201217-WA0101-142x300.jpg)